Valeant Pharmaceuticals announced that its affiliate has completed the sale of the Sprout Pharmaceuticals subsidiary (“Sprout”) to Sprout2. Sprout2 is affiliated with certain former shareholders of Sprout, in exchange for a 6% royalty on global sales of ADDYI (flibanserin) beginning in May 2019. In connection with the sale, Valeant has provided a $25 million loan to fund initial operating expenses.   In connection with the completion of the sale, Valeant has been released fro...